Open AccessThe Therapeutic Potential of Synthetic and Natural Cannabinoids in Treating Alzheimer’s Disease
Author(s) -
Nidhi Kanchumarthi,
Avigail Rockland,
Thejaswini Vembar,
Elaine Liu,
Rithvik Kanaad,
Erick Torres Hinojosa,
Kira Tiv,
Benjamin Chen,
Shira Hao,
Sri Guttikonda,
Ramiro Garza
Publication year - 2021
Publication title -
berkeley pharma tech journal of medicine
Language(s) - English
Resource type - Journals
ISSN - 2771-7895
DOI - 10.52243/bptjm.v1i1.12
Subject(s) - cannabidiol , endocannabinoid system , neurodegeneration , synthetic cannabinoids , neuroscience , medicine , disease , cannabinoid , neurotoxicity , tetrahydrocannabinol , alzheimer's disease , pharmacology , cannabis , psychology , psychiatry , toxicity , receptor
Alzheimer’s disease (AD) is one of the most prevalent and debilitating neurodegenerative diseases in the world, highlighting the need for research on novel treatments and therapies. Previous studies have found that the body’s endocannabinoid system (ECS) interacts closely with its neural system, making it a potential avenue for the treatment of neurological disorders. One hallmark of AD is the accumulation of amyloid-beta (Aβ) in the brain and its potentially detrimental effects on cognitive function. Cannabis-based drugs have been observed to regulate Aβ modifications and inhibit AD progression. Furthermore, cannabinoids have been noted to reduce inflammation and neurotoxicity. Synthetic cannabinoids were able to rescue memory deficits and neurodegeneration, and reduce immunoreactivity. Similarly, natural cannabinoids like Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) demonstrate therapeutic potential by interacting with the cholinergic system, and reversing the symptoms of AD. Although further research and testing are needed, it is evident that the use of cannabinoids shows promise for future treatment in AD patients.